David B Finlay (David Finlay)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 25

Top Venues

British journal of pharmacology

ACS pharmacology & translational science

Pharmaceuticals (Basel, Switzerland)

ACS chemical neuroscience

University of Otago

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Otago

New Zealand

Postdoctoral Felow :: Pharmacology and Toxicology

Publications

Hayley M Green, Daniel M J Fellner, David B Finlay, Daniel P Furkert, Michelle Glass
Determination of the Cannabinoid CB1 Receptor's Positive Allosteric Modulator Binding Site through Mutagenesis Studies. Pharmaceuticals (Basel, Switzerland) 17 (2) (2024)
Hayley M Green, Daniel M J Fellner, David B Finlay, Daniel P Furkert, Michelle Glass
Determination of the Cannabinoid CB1 Receptor's Positive Allosteric Modulator Binding Site through Mutagenesis Studies. Pharmaceuticals (Basel, Switzerland) 17 (2) (2024)
Hayley M Green, Jamie J Manning, Ian R Greig, Ruth A Ross, David B Finlay, Michelle Glass
Positive allosteric modulation of the cannabinoid CB 1 receptor potentiates endocannabinoid signalling and changes ERK1/2 phosphorylation kinetics. British journal of pharmacology 181 (19) (2024)
Hayley M Green, Jamie J Manning, Ian R Greig, Ruth A Ross, David B Finlay, Michelle Glass
Positive allosteric modulation of the cannabinoid CB 1 receptor potentiates endocannabinoid signalling and changes ERK1/2 phosphorylation kinetics. British journal of pharmacology (2024)
Liang Yang, David B Finlay, Hayley M Green, Xiao Zhu, Michelle Glass, Stephen Duffull
A quantitative pharmacology model for cannabinoid receptor type 1 (CB 1 ) mediated by Gi/Gs protein competition. British journal of pharmacology (2023)
Liang Yang, Xiao Zhu, David B Finlay, Hayley Green, Michelle Glass, Stephen B Duffull
A kinetic model for positive allosteric modulator (PAM)-antagonists for the type 1 cannabinoid receptor (CB 1 ). British journal of pharmacology (2023)
Nathaniel A K Glenn, David B Finlay, Emma R Carruthers, Kathleen G Mountjoy, Christopher S Walker, Natasha L Grimsey
RAMP and MRAP Accessory Proteins have Selective Effects on Expression and Signalling of the CB1, CB2, GPR18 and GPR55 Cannabinoid Receptors. British journal of pharmacology (2023)
Monica Patel, Natasha L Grimsey, Samuel D Banister, David B Finlay, Michelle Glass
Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB 2 receptor. Pharmacology research & perspectives 11 (6) (2023)
Nathaniel A K Glenn, David B Finlay, Emma R Carruthers, Kathleen G Mountjoy, Christopher S Walker, Natasha L Grimsey
RAMP and MRAP Accessory Proteins have Selective Effects on Expression and Signalling of the CB1, CB2, GPR18 and GPR55 Cannabinoid Receptors. British journal of pharmacology (2023)
Nathaniel A K Glenn, David B Finlay, Emma R Carruthers, Kathleen G Mountjoy, Christopher S Walker, Natasha L Grimsey
RAMP and MRAP Accessory Proteins have Selective Effects on Expression and Signalling of the CB1, CB2, GPR18 and GPR55 Cannabinoid Receptors. British journal of pharmacology (2023)
Nathaniel A K Glenn, David B Finlay, Emma R Carruthers, Kathleen G Mountjoy, Christopher S Walker, Natasha L Grimsey
RAMP and MRAP Accessory Proteins have Selective Effects on Expression and Signalling of the CB1, CB2, GPR18 and GPR55 Cannabinoid Receptors. British journal of pharmacology (2023)
Jamie J Manning, Gabriel Rawcliffe, David B Finlay, Michelle Glass
Cannabinoid 1 (CB 1 ) receptor arrestin subtype-selectivity and phosphorylation dependence. British journal of pharmacology (2022)
Hayley M Green, David B Finlay, Ruth A Ross, Iain R Greig, Stephen B Duffull, Michelle Glass
In Vitro Characterization of 6-Methyl-3-(2-nitro-1-(thiophen-2-yl)ethyl)-2-phenyl-1 H -indole (ZCZ011) at the Type 1 Cannabinoid Receptor: Allosteric Agonist or Allosteric Modulator? ACS pharmacology & translational science 5 (12) (2022)
Hayley M Green, David B Finlay, Ruth A Ross, Iain R Greig, Stephen B Duffull, Michelle Glass
In Vitro Characterization of 6-Methyl-3-(2-nitro-1-(thiophen-2-yl)ethyl)-2-phenyl-1 H -indole (ZCZ011) at the Type 1 Cannabinoid Receptor: Allosteric Agonist or Allosteric Modulator? ACS pharmacology & translational science 5 (12) (2022)
Jack Markham, Eric Sparkes, Rochelle Boyd, Shuli Chen, Jamie J Manning, David B Finlay, Felcia Lai, Eila McGregor, Callan J Maloney, Roy R Gerona, Mark Connor, Iain S McGregor, David E Hibbs, Michelle Glass, Richard C Kevin, Samuel D Banister
Defining Steric Requirements at CB 1 and CB 2 Cannabinoid Receptors Using Synthetic Cannabinoid Receptor Agonists 5F-AB-PINACA, 5F-ADB-PINACA, PX-1, PX-2, NNL-1, and Their Analogues. ACS chemical neuroscience 13 (8) (2022)
David B Finlay, Thuy Nguyen, Thomas F Gamage, Shuli Chen, Daniel G Barrus, Purvi R Patel, Brian F Thomas, Jenny L Wiley, Yanan Zhang, Michelle Glass
Exploring determinants of agonist efficacy at the CB1 cannabinoid receptor: Analogues of the synthetic cannabinoid receptor agonist EG-018. Pharmacology research & perspectives 10 (1) (2022)
Monica Patel, Christoph Matti, Natasha L Grimsey, Daniel F Legler, Jonathan A Javitch, David B Finlay, Michelle Glass
Delineating the interactions between the cannabinoid CB2 receptor and its regulatory effectors; β-arrestins and G protein-coupled receptor kinases. British journal of pharmacology (2021)
Liang Yang, Xiao Zhu, David B Finlay, Michelle Glass, Stephen B Duffull
Exploring group size for statistical analysis of real-time signalling experiments. British journal of pharmacology 178 (19) (2021)
Thuy Nguyen, Thomas F Gamage, David B Finlay, Ann M Decker, Tiffany L Langston, Daniel Barrus, Michelle Glass, Jun-Xu Li, Terry P Kenakin, Yanan Zhang
Development of 3-(4-Chlorophenyl)-1-(phenethyl)urea Analogues as Allosteric Modulators of the Cannabinoid Type-1 Receptor: RTICBM-189 is Brain Penetrant and Attenuates Reinstatement of Cocaine-Seeking Behavior. Journal of medicinal chemistry 65 (1) (2021)
David B Finlay, Stephen B Duffull, Michelle Glass
100 years of modelling ligand-receptor binding and response: A focus on GPCRs. British journal of pharmacology 177 (7) (2020)
Xiao Zhu, David B Finlay, Michelle Glass, Stephen B Duffull
Evaluation of the profiles of CB1 cannabinoid receptor signalling bias using joint kinetic modelling. British journal of pharmacology 177 (15) (2020)
David B Finlay, Jamie J Manning, Mikkel Søes Ibsen, Christa E Macdonald, Monica Patel, Jonathan A Javitch, Samuel D Banister, Michelle Glass
Do Toxic Synthetic Cannabinoid Receptor Agonists Have Signature in Vitro Activity Profiles? A Case Study of AMB-FUBINACA. ACS chemical neuroscience 10 (10) (2019)
Xiao Zhu, David B Finlay, Michelle Glass, Stephen B Duffull
Model-free and kinetic modelling approaches for characterising non-equilibrium pharmacological pathway activity: Internalisation of cannabinoid CB1 receptors. British journal of pharmacology 176 (14) (2019)
Xiao Zhu, David B Finlay, Michelle Glass, Stephen B Duffull
An intact model for quantifying functional selectivity. Scientific reports 9 (1) (2019)
David B Finlay, Erin E Cawston, Natasha L Grimsey, Morag Rose Hunter, Anisha Korde, V Kiran Vemuri, Alexandros Makriyannis, Michelle Glass
Gαs signalling of the CB1 receptor and the influence of receptor number. British journal of pharmacology 174 (15) (2017)

David B Finlay.css-eqlu8i{font-size:small;padding-left:4px;} (David Finlay)

Publication Activity (10 Years)

Top Topics

Top Venues

David B Finlay (David Finlay)